<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904199</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19637</org_study_id>
    <nct_id>NCT03904199</nct_id>
  </id_info>
  <brief_title>Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia</brief_title>
  <official_title>A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the outcomes between hospitalized cancer patients
      with high blood sugar receiving the current standard of care of administering insulin, and
      hospitalized cancer patients receiving a new, individualized method of insulin
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">April 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of blood glucose values within normal range</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of high blood glucose levels</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values &gt;180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of low blood glucose levels</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values &lt;70 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of normal blood glucose level</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Duration of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Basal-Prandial-Correctional Insulin Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Insulin Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Participants will receive long-acting insulin and/or rapid-acting insulin per protocol</description>
    <arm_group_label>Basal-Prandial-Correctional Insulin Regimen</arm_group_label>
    <arm_group_label>Standard of Care Insulin Regimen</arm_group_label>
    <other_name>Basal insulin</other_name>
    <other_name>Prandial insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent form

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Provide race and ethnicity information

          -  Male or female, aged 18 years or greater

          -  Diagnosed with cancer

          -  Hospitalized at MCC in the medical, hematologic, or bone marrow transplant units

          -  Having in-hospital hyperglycemia with or without a pre-existing diagnosis of DM, with
             2 measurements of BG &gt; 180 mg/dL and/or 1 measurement of BG &gt; 350mg/dL within the
             first 48 hours of hospitalization, detected by bedside point-of-care testing and/or
             basic metabolic panel laboratory data.

          -  Participants enrolled in other clinical trials are admissible to this trial.

        Exclusion Criteria:

          -  An individual who meets any of the following criteria will be excluded from
             participation in this study:

          -  Participants &lt; 18 years of age

          -  Participants at the end of life and/or with limited life expectancies (&lt; 6 months)

          -  Participants without cancer diagnoses

          -  Surgical patients and patients admitted directly to the intensive care unit, other
             than those in the Bone Marrow Transplant Unit, who are included

          -  Participants treated and discharged in outpatient settings (ie, direct referral
             center, infusion center, or clinical research unit) or those admitted for observation
             only (hospitalized less than 24 hours)

          -  Participants on total parenteral nutrition

          -  Participants on insulin pumps

          -  Participants admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar
             syndrome

          -  Pregnant Participants based on medical history

          -  Participants being followed by endocrinology for hyperglycemia or hypoglycemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smitha Pabbathi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cienna Wesley</last_name>
      <phone>813-745-3861</phone>
      <email>Cienna.Wesley@Moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Smitha Pabbathi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica Alvarez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celeste Bello, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Giuliano, PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Hallanger Johnson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Hembree, D.O. PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffery Lancet, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Locke, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asha Ramsakal, D.O. MBS FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neha Verma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Blood Sugar</keyword>
  <keyword>High Blood Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

